文献速递肝肾功能剂量调整特殊人群用药治疗药物监测与药物基因组学

庆大霉素在不同患者群体中的临床药代动力学及革兰阴性菌感染最佳给药综述

Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review.
PubMed 文献 · Clin Pharmacokinet · 2022-06-27

本综述总结了近10年关于庆大霉素在肥胖、危重症、儿科、新生儿、老年及透析患者中的群体药代动力学研究,发现起始剂量按总体重7 mg/kg(肥胖者按调整体重)可提高成人及>1月龄儿童的目标 attainment 概率,但缺乏其与临床疗效相关性的证据;建议高危患者进行TDM,并将谷浓度控制在<2 mg/L(最好<0.5-1 mg/L)以减少肾毒性。

要点

  • 起始剂量7 mg/kg(总体重;肥胖者调整体重)可提高成人及>1月龄儿童首次给药PTA。
  • 危重症、老年、儿童、新生儿及间歇性血透患者建议TDM优化PTA。
  • 多剂给药者应TDM优化给药间隔,谷浓度至少<2 mg/L,最好<0.5-1 mg/L以降低肾毒性。

核心结论

  • 庆大霉素起始剂量7 mg/kg(总体重;肥胖者调整体重)可提高成人及>1月龄儿童首次给药PTA,但缺乏其与临床疗效相关性的证据。
  • TDM推荐用于药代动力学变异大的患者(危重症各亚群及间歇性血透),以优化PTA和给药间隔,谷浓度<2 mg/L(最好<0.5-1 mg/L)可减少肾毒性。

研究设计与样本

  • 综述总结了近10年关于庆大霉素在肥胖、危重症、儿科、新生儿、老年及透析患者中的群体药代动力学研究。

主要发现

  • 近10年多项群体药代动力学研究提供了关键参数典型值、变异性及可能解释,但未解释的变异性常仍较高。
  • 各研究的给药方案和PK/PD目标差异很大。
  • 未发现估算或预测的PK/PD达标与临床成功相关的研究。
  • 每日AUC用于预测肾毒性的价值有待进一步研究。

关键数值与推荐

  • 成人及>1月龄儿童(含危重症)起始剂量7 mg/kg(总体重;肥胖者调整体重)可提高常用PK/PD目标的PTA。
  • 多剂给药者TDM优化给药间隔,目标谷浓度至少<2 mg/L,最好<0.5-1 mg/L。
  • 危重症各亚群(老年、儿童、新生儿)及间歇性血透患者建议TDM优化PTA。

临床怎么用

  • 成人及>1月龄儿童(含危重症)经验性治疗起始剂量可按7 mg/kg(总体重;肥胖者调整体重)给药。
  • 危重症、老年、儿童、新生儿及间歇性血透患者建议进行TDM以优化PTA。
  • 接受多剂庆大霉素者应TDM优化给药间隔,维持谷浓度<2 mg/L(最好<0.5-1 mg/L)以降低肾毒性。

局限性

  • 未发现PK/PD达标与临床成功相关的研究,PTA提高是否带来疗效获益缺乏证据。
  • 各研究给药方案和PK/PD目标差异大,未解释的药代动力学变异性常仍较高。
  • 每日AUC预测肾毒性的价值尚不明确,需进一步研究。
  • 庆大霉素当前用于尿路感染单药或短期联合治疗,其最佳PK/PD疗效目标需更多研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gentamicin is an aminoglycoside antibiotic with a small therapeutic window that is currently used primarily as part of short-term empirical combination therapy. Gentamicin dosing schemes still need refinement, especially for subpopulations where pharmacokinetics can differ from pharmacokinetics in the general adult population: obese patients, critically ill patients, paediatric patients, neonates, elderly patients and patients on dialysis. This review summarizes the clinical pharmacokinetics of gentamicin in these patient populations and the consequences for optimal dosing of gentamicin for infections caused by Gram-negative bacteria, highlighting new insights from the last 10 years. In this period, several new population pharmacokinetic studies have focused on these subpopulations, providing insights into the typical values of the most relevant pharmacokinetic parameters, the variability of these parameters and possible explanations for this variability, although unexplained variability often remains high. Both dosing schemes and pharmacokinetic/pharmacodynamic (PK/PD) targets varied widely between these studies. A gentamicin starting dose of 7 mg/kg based on total body weight (or on adjusted body weight in obese patients) appears to be the optimal strategy for increasing the probability of target attainment (PTA) after the first administration for the most commonly used PK/PD targets in adults and children older than 1 month, including critically ill patients. However, evidence that increasing the PTA results in higher efficacy is lacking; no studies were identified that show a correlation between estimated or predicted PK/PD target attainment and clinical success. Although it is unclear if performing therapeutic drug monitoring (TDM) for optimization of the PTA is of clinical value, it is recommended in patients with highly variable pharmacokinetics, including patients from all subpopulations that are critically ill (such as elderly, children and neonates) and patients on intermittent haemodialysis. In addition, TDM for optimization of the dosing interval, targeting a trough concentration of at least < 2 mg/L but preferably < 0.5-1 mg/L, has proven to reduce nephrotoxicity and is therefore recommended in all patients receiving more than one dose of gentamicin. The usefulness of the daily area under the plasma concentration-time curve for predicting nephrotoxicity should be further investigated. Additionally, more research is needed on the optimal PK/PD targets for efficacy in the clinical situations in which gentamicin is currently used, that is, as monotherapy for urinary tract infections or as part of short-term combination therapy.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Hodiamont CJ, van den Broek AK, de Vroom SL, et al. Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review. Clin Pharmacokinet. 2022. PMID: 35754071. doi:10.1007/s40262-022-01143-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。